Wegovy 1mg

Wegovy 1mg Injection refers to semaglutide at 2mg/mL; the active ingredient of the drug; a prescription product for weight management which is injected once a week. The picture shows Wegovy FlexTouch 1mg, a pen which is ready for use and contains subcutaneous doses.

Wegovy has approval in Australia. The TGA records Wegovy FlexTouch 1mg as an ARTG medicine approved drug (ARTG 424392), of which semaglutide is the active ingredient. The article explains Wegovy FlexTouch 1mg in detail in the image.

What Is Wegovy 1mg Used For?

Wegovy is composed of semaglutide, a GLP-1 receptor agonist, indicated for chronic weight management, which includes weight loss and weight maintenance。

Wegovy is approved for adult use only in conjunction with a low-calorie diet and increased physical activity for individuals with the following:

• Obesity (BMI of at least 30kg/m²) or
• Overweight (17-27kg/m²) with one of the health conditions related to being overweight.

Additionally, the drug is approved in Australia for weight management of certain adolescents aged at least 12 years who are obese and whose body weight exceeds 60 kg.

Wegovy can only be prescribed by a doctor. Please use it under medical supervision.

How Does Wegovy 1mg Work?

Semaglutide targets GLP-1 receptors which are key in appetite control, food intake and glycemic regulation.

It may offer assistance in:

• Curbing the feeling of hunger
• Enhancing the sense of satiety
• Limiting how much one eats overall
• Paving the stomach to empty at a slower rate
• Providing support to keep the pounds off over time

All these benefits help you stay below your daily food calorific limit. However, Wegovy is only an addition to, not a substitute for, healthy diet choices and exercise.

How To Use Wegovy 1mg

Wegovy 1mg is administered once weekly by subcutaneous injection.

It can be injected under the skin of the:

• Abdomen
• Thigh
• Upper arm

Wegovy can be administered at any time of day, with or without meals. It should not be injected into a vein or muscle. The injection site can be changed without changing the dose.

The FlexTouch pen should be used according to the instructions supplied with the product. A healthcare professional should demonstrate the correct injection technique before self-administration.

Do not share the pen with another person.

Wegovy 1mg Dosage

The 1mg dose is part of the gradual semaglutide dose-escalation schedule:

Treatment period	Weekly dose
Weeks 1–4	0.25mg
Weeks 5–8	0.5mg
Weeks 9–12	1mg
Weeks 13–16	1.7mg
Maintenance	2.4mg

Therefore, 1mg once weekly is normally used during weeks 9–12 before treatment progresses to 1.7mg and eventually the 2.4mg maintenance dose, if tolerated.

The gradual increase is intended to reduce gastrointestinal side effects. If significant digestive symptoms occur, dose escalation can be delayed until symptoms improve.

Do not increase or decrease your Wegovy dose without medical advice.

What If You Miss a Wegovy 1mg Dose?

If the dose for one week is forgotten, take it as soon as possible but within 5 days only.

If the time between the missed dose and the next dose is more than 5 days, it is advised not to take the missed dose and take the next one on the normally scheduled day.

Be advised that you should not take two doses close together as a means of making up a missed injection.

If multiple injections have been missed, your doctor might decide to restarting with the lowest possible dosage.

Possible Side Effects

Common side effects of Wegovy include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal pain
• Indigestion
• Headache
• Tiredness
• Dizziness
• Injection-site reactions

Digestive symptoms often present themselves as a side effect when initiating drug therapy or when the dose is escalated.

Cheerless vomiting or continuous diarrhea are among the chief signs of water loss through the body. Such a loss of fluids causes the blood to become more concentrated making the kidneys work harder and possibly leading to kidney failure in patients already suffering from kidney disorders.

In case you experience severe and continuing abdominal pain that especially spreads to your back, you need to consult your doctor urgently since it might indicate acute pancreatitis.

Precautions Before Using Wegovy

Tell your doctor before using Wegovy if you have:

• A history of pancreatitis
• Severe gastrointestinal disease or delayed stomach emptying
• Kidney problems
• Gallbladder problems or gallstones
• Diabetic retinopathy
• A history of serious allergic reactions to semaglutide
• Diabetes treated with insulin or sulfonylureas
• A planned operation or procedure involving general anaesthesia or deep sedation

Semaglutide is contraindicated in pregnant women. According to the Australian product insert, if a pregnancy is detected, the treatment should be stopped. In addition, a woman should stop taking semaglutide two months prior to planned pregnancy due to its long half-life.

Wegovy 1mg and Other Medicines

Lets your physician know of all the prescription medicines, diabetes medicines, supplements, and other weight management medicines that you use.

The combined use of Wegovy and either insulin or sulfonylureas may result in an increased risk of hypoglycemia. Hence the doses of such medicines might require adjustment by your doctor.

Semaglutide can slow the emptying of the stomach, possibly affecting the absorption of mouth administered medicines. The product information from Australia says that extra care may be required for oral medicines that require fast gastrointestinal absorption。

Combining Wegovy with another semaglutide-based medicine or another GLP-1 receptor agonist is not advisable unless your healthcare provider has given you precise instructions.

Storage

Wegovy 1mg should be stored correctly to maintain the quality of the medicine.

Australian product information states:

• Store at 2°C to 8°C
• Keep away from the cooling element
• Protect from light
• Do not freeze
• Protect from excessive heat

Wegovy may be stored unrefrigerated for up to 28 days at a temperature not above 30°C, according to the Australian product information. Keep the pen in its original carton to protect it from light.

Do not use the medicine if it has been frozen or if the solution does not appear clear and colourless.

Frequently Asked Questions

Is Wegovy 1mg enough to be considered a maintenance dose?

For the standard adult weight-management schedule, 1mg is an escalation dose rather than the usual maintenance dose. It is normally used during weeks 9–12 before increasing to 1.7mg and then 2.4mg if tolerated. 

Can Wegovy 1mg be used by older adults?

Australian product information states that no dose adjustment is required based on age. However, treatment decisions should still take into account other medical conditions, medicines and individual tolerability. Experience in people aged 75 years and older is limited.

Can Wegovy 1mg affect my stomach for several days after the injection?

Yes. Semaglutide has a long half-life of approximately one week, which supports once-weekly dosing. Its effects on digestion can therefore continue between injections.

Is Wegovy 1mg suitable if I have kidney disease?

This depends on the severity of the kidney condition. Australian product information states that no routine dose adjustment is required for renal impairment, but experience in severe renal impairment is limited and semaglutide is not recommended in end-stage renal disease. Your doctor should assess your individual situation.

Can Wegovy 1mg be used indefinitely?

Wegovy is intended for chronic weight management, including both weight loss and weight maintenance. Whether treatment should continue long term depends on your response, side effects, health goals and your healthcare professional’s assessment.

References

• TGA – Wegovy FlexTouch 1mg, ARTG 424392 TGA Wegovy FlexTouch 1mg
• TGA – Wegovy Australian Product Information Wegovy Product Information
• Healthdirect – Wegovy FlexTouch Healthdirect Wegovy FlexTouch

Medical Disclaimer

Wegovy 1mg is a prescription medicine and should only be used under the supervision of a qualified healthcare professional. This information is provided for educational purposes and does not replace personalised medical advice, diagnosis or treatment.